ES2248581T3
(es)
|
2001-03-12 |
2006-03-16 |
Intercept Pharmaceuticals, Inc. |
Esteroides como agonistas de fxr.
|
US10987362B2
(en)
|
2004-03-12 |
2021-04-27 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
US9498484B2
(en)
|
2004-03-12 |
2016-11-22 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
ITMI20050912A1
(it)
*
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
WO2008002573A2
(en)
|
2006-06-27 |
2008-01-03 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
WO2008091540A2
(en)
|
2007-01-19 |
2008-07-31 |
Intercept Pharmaceuticals, Inc. |
23-substituted bile acids as tgr5 modulators and methods of use thereof
|
US8338628B2
(en)
*
|
2007-08-28 |
2012-12-25 |
City Of Hope |
Method of synthesizing alkylated bile acid derivatives
|
US8796249B2
(en)
|
2008-07-30 |
2014-08-05 |
Intercept Pharmaceuticals, Inc. |
TGR5 modulators and methods of use thereof
|
KR101667436B1
(ko)
|
2008-11-19 |
2016-10-18 |
인터셉트 파마슈티컬즈, 인크. |
Tgr5 조절제 및 그의 사용 방법
|
WO2010069604A1
(en)
|
2008-12-19 |
2010-06-24 |
Royal College Of Surgeons In Ireland |
Treatment of diarrhoea
|
EP2255813A1
(en)
*
|
2009-05-29 |
2010-12-01 |
The Royal College of Surgeons in Ireland |
Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
|
US8258485B2
(en)
*
|
2010-08-30 |
2012-09-04 |
Media Lario Srl |
Source-collector module with GIC mirror and xenon liquid EUV LPP target system
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
EA032347B1
(ru)
*
|
2012-06-19 |
2019-05-31 |
Интерсепт Фармасьютикалз, Инк. |
Получение, применение и твердые формы обетихолевой кислоты
|
AU2013334122B2
(en)
*
|
2012-10-26 |
2017-11-02 |
Intercept Pharmaceuticals, Inc. |
Process for preparing bile acid derivatives
|
JP6326131B2
(ja)
*
|
2013-05-14 |
2018-05-16 |
インターセプト ファーマシューティカルズ, インコーポレイテッド |
ファルネソイドx受容体調節物質としての、胆汁酸の11−ヒドロキシル誘導体およびそのアミノ酸抱合体
|
MX2015017035A
(es)
|
2013-06-13 |
2016-04-25 |
Fast Forward Pharmaceuticals B V |
Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
|
AU2014320463B2
(en)
|
2013-09-11 |
2018-08-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
|
CN107075515B
(zh)
|
2013-11-22 |
2020-10-30 |
米纳治疗有限公司 |
C/EBPα组合物和使用方法
|
MX2020004024A
(es)
|
2014-05-29 |
2021-12-10 |
Bar Pharmaceuticals S R L |
Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1.
|
RU2017118569A
(ru)
|
2014-11-06 |
2018-12-06 |
Энанта Фармасьютикалс, Инк. |
Аналоги желчных кислот как агонисты fxr/tgr5 и способы их применения
|
TWI686401B
(zh)
*
|
2014-11-19 |
2020-03-01 |
英商Nzp英國有限公司 |
化合物(三)
|
DK3221332T3
(da)
|
2014-11-19 |
2019-07-29 |
Nzp Uk Ltd |
Fremstilling af steroide fxr-modulatorer
|
CA2968309A1
(en)
|
2014-11-19 |
2016-05-26 |
NZP UK Limited |
6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
|
MX2017006567A
(es)
|
2014-11-19 |
2018-01-26 |
Nzp Uk Ltd |
Esteroides 6.alfa.-alquil-6,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
|
BR112017010893A2
(pt)
|
2014-11-26 |
2018-02-06 |
Enanta Pharm Inc |
análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
WO2016086115A1
(en)
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
|
KR20170115071A
(ko)
|
2015-02-06 |
2017-10-16 |
인터셉트 파마슈티컬즈, 인크. |
병용 요법을 위한 약제학적 조성물
|
BR112017017238A2
(pt)
|
2015-02-11 |
2018-04-10 |
Enanta Pharm Inc |
análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
|
CN105985396A
(zh)
*
|
2015-02-16 |
2016-10-05 |
苏州泽璟生物制药有限公司 |
氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
|
RS62110B1
(sr)
|
2015-03-31 |
2021-08-31 |
Enanta Pharm Inc |
Derivati žučnih kiselina kao agonisti fxr/tgr5 i postupci njihove upotrebe
|
EA036757B1
(ru)
|
2015-04-07 |
2020-12-17 |
Интерсепт Фармасьютикалз, Инк. |
Фармацевтические композиции для комбинированной терапии
|
CN105777836A
(zh)
*
|
2015-04-09 |
2016-07-20 |
厦门蔚扬药业有限公司 |
奥贝胆酸的多晶型物及其制备方法
|
WO2016173524A1
(zh)
*
|
2015-04-29 |
2016-11-03 |
正大天晴药业集团股份有限公司 |
鹅去氧胆酸衍生物
|
EP3124080A1
(en)
|
2015-07-28 |
2017-02-01 |
Merz Pharma GmbH & Co. KGaA |
Semisynthetic bile acids for injection lipolysis
|
CN105175473B
(zh)
*
|
2015-08-19 |
2018-12-21 |
丽珠医药集团股份有限公司 |
一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
|
CN106632564B
(zh)
*
|
2015-10-30 |
2021-04-13 |
苏州泽璟生物制药股份有限公司 |
奥贝胆酸盐及其无定形物和药物组合物
|
CN106749466B
(zh)
*
|
2015-11-23 |
2019-05-21 |
南京济群医药科技股份有限公司 |
一种高纯度奥贝胆酸的制备方法
|
CN105315320B
(zh)
*
|
2015-11-30 |
2017-03-08 |
山东省药学科学院 |
一种制备奥贝胆酸的方法
|
CN106810587A
(zh)
*
|
2015-12-01 |
2017-06-09 |
中美华世通生物医药科技(武汉)有限公司 |
制备无定型奥贝胆酸的方法
|
CN106810586A
(zh)
*
|
2015-12-01 |
2017-06-09 |
中美华世通生物医药科技(武汉)有限公司 |
奥贝胆酸晶型ⅱ及其制备方法和用途
|
EP3409684B1
(en)
*
|
2016-01-28 |
2024-01-03 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Steroid derivative fxr agonist
|
US20170233431A1
(en)
|
2016-02-17 |
2017-08-17 |
City Of Hope |
Bile acid derivatives and methods for synthesis and use
|
WO2017147159A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
US10323061B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
WO2017147137A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
|
TWI740922B
(zh)
*
|
2016-03-31 |
2021-10-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種奧貝膽酸的新結晶形式及其製備方法
|
TW201738254A
(zh)
*
|
2016-04-19 |
2017-11-01 |
英特賽普醫藥品公司 |
奧貝膽酸及其衍生物之製備方法
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
EA038580B9
(ru)
*
|
2016-05-18 |
2021-10-05 |
Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. |
Агонист fxr, представляющий собой производное стероидов
|
WO2017207648A1
(en)
|
2016-05-31 |
2017-12-07 |
Bionice, S.L.U |
Process and intermediates for the preparation of obeticholic acid and derivatives thereof
|
WO2018010651A1
(zh)
*
|
2016-07-13 |
2018-01-18 |
江苏恒瑞医药股份有限公司 |
一种奥贝胆酸及其中间体的制备方法
|
AU2017368069B2
(en)
|
2016-11-29 |
2021-07-08 |
Enanta Pharmaceuticals, Inc. |
Process for preparation of sulfonylurea bile acid derivatives
|
WO2018152171A1
(en)
|
2017-02-14 |
2018-08-23 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr agonists and methods of use thereof
|
WO2018153933A1
(en)
|
2017-02-21 |
2018-08-30 |
Genfit |
Combination of a ppar agonist with a fxr agonist
|
JP2020514337A
(ja)
*
|
2017-03-08 |
2020-05-21 |
インターセプト ファーマシューティカルズ, インコーポレイテッド |
オベチコール酸の結晶形態
|
CN110944635A
(zh)
|
2017-03-30 |
2020-03-31 |
国家医疗保健研究所 |
用于减少附加体病毒的持久性和表达的方法和药物组合物
|
BR112019020780A2
(pt)
|
2017-04-07 |
2020-04-28 |
Enanta Pharm Inc |
processo para preparação de derivados de ácido biliar de carbamato de sulfonila
|
KR20200010483A
(ko)
|
2017-05-26 |
2020-01-30 |
메드샤인 디스커버리 아이엔씨. |
Fxr 수용체 작용제로서 락탐 화합물
|
CN109021056B
(zh)
*
|
2017-06-09 |
2021-03-09 |
博瑞生物医药(苏州)股份有限公司 |
法尼酯x受体激动剂
|
EP3679138B1
(en)
|
2017-09-08 |
2023-03-22 |
MiNA Therapeutics Limited |
Hnf4a sarna compositions and methods of use
|
GB201812382D0
(en)
|
2018-07-30 |
2018-09-12 |
Nzp Uk Ltd |
Compounds
|
WO2020039449A1
(en)
|
2018-08-24 |
2020-02-27 |
Solara Active Pharma Sciences Limited |
An improved process for the preparation of obeticholic acid and intermediates used in the process thereof
|
CA3121020A1
(en)
*
|
2018-11-26 |
2020-06-04 |
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. |
Solid form, crystalline form, and crystal form a of fxr agonist, and preparation method therefor and application thereof
|
EA202193334A1
(ru)
|
2019-05-30 |
2022-03-14 |
Интерсепт Фармасьютикалз, Инк. |
Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени
|
EP3999101A1
(en)
|
2019-07-18 |
2022-05-25 |
ENYO Pharma |
Method for decreasing adverse-effects of interferon
|
US20230146782A1
(en)
*
|
2019-08-06 |
2023-05-11 |
Du Jessica Xinyun |
Deoxycholic acid compounds, pharmaceutical compositions and uses thereof
|
IL293892A
(en)
|
2020-01-15 |
2022-08-01 |
Inserm Institut National De La Sant? Et De La Rech M?Dicale |
Use of fxr agonists to treat hepatitis d virus infection
|
US20240100125A1
(en)
|
2021-01-14 |
2024-03-28 |
Enyo Pharma |
Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
|
TW202308629A
(zh)
|
2021-04-28 |
2023-03-01 |
法商Enyo製藥公司 |
使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
|